In our cohort, two out of 5 patients with de novo AML and CSF3R pathogenic variants in the cytoplasmic tail were found to be primary refractory to induction therapy, comprising one case with NPM1-mutated AML and ELN favorable risk. This evidence concerns the gene NPM1 and acute myeloid leukemia.